<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03369990</url>
  </required_header>
  <id_info>
    <org_study_id>DW_DWP450008</org_study_id>
    <nct_id>NCT03369990</nct_id>
  </id_info>
  <brief_title>DWP450 Treatment in Subjects With Benign Masseteric Hypertrophy</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Phase â…¡ Optimal Dose-finding Study to Determine the Safety and Efficacy of DWP450 in Subjects With Benign Masseteric Hypertrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daewoong Pharmaceutical Co. LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daewoong Pharmaceutical Co. LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is A Randomized, Double-blind, Placebo-controlled, Phase II Optimal Dose-finding
      Study to Determine the Safety and Efficacy of DWP450 in Subjects with Benign Masseteric
      Hypertrophy
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2017</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction amount of masseter muscle thickness</measure>
    <time_frame>At 12 weeks</time_frame>
    <description>Reduction amount of masseter muscle thickness by Ultrasonography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction amount of masseter muscle thickness</measure>
    <time_frame>At 4,8,16 weeks</time_frame>
    <description>Reduction amount of masseter muscle thickness by Ultrasonography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction amount of lower face volume</measure>
    <time_frame>At 4, 8, 12, 16 weeks</time_frame>
    <description>Reduction amount of lower face volume by 3D digital imaging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall satisfaction of subject</measure>
    <time_frame>At 4, 8, 12, 16 weeks</time_frame>
    <description>Overall satisfaction of subject by questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Benign Masseteric Hypertrophy</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin type A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DWP450</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin type A</intervention_name>
    <description>Botulinum toxin type A(DWP450)</description>
    <arm_group_label>Botulinum toxin type A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Normal Saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subject over 18 years of age and written informed consent is obtained.

          2. Subject with Benign Masseter Hypertrophy

          3. Subject who has Bisymmetry of masseter at visual assessment.

          4. Subjects who meets thickness of Masseter muscle by ultrasonography.

          5. Subjects who can and will comply with the requirements of the protocol.

        Exclusion Criteria:

          1. Diagnosis of Myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis,
             or any other condition that might interfere with neuromuscular function

          2. Subject who got any treatment, including double jaw surgery, laser, thread treatment
             etc. in 12 months.

          3. Subject who had previously received botulinum toxin within 3 months prior to the study
             entry

          4. Subject with known hypersensitivity to botulinum toxin

          5. Subject who are pregnant or lactating or found pregnancy though the urine or sebum
             test or disagreed to avoid pregnancy during study period.

          6. Subjects who are not eligible for this study at the discretion of the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 26, 2017</study_first_submitted>
  <study_first_submitted_qc>December 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2017</study_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

